Skip to content

New ayurvedic formulation regime in moderate COVID-19 patients

Evaluation of new Ayurvedic formulations regime in moderate COVID 19 patients - Regime

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/07/034769
Enrollment
60
Registered
2021-07-12
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

Intervention1: Formula P, F & L: Three formulations of drugs being given- 1.Formula P Main Ingredients-Arka pushpa, Jambupatra pallava, Nimbapatra pallva, Vilvapatra pallava, Devadali Prakshepakas- U

Sponsors

Bonigi Anandaiah
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Moderate COVID- 19 confirmed participants of age > 18 years, both sexes and willing to participate with consent. WHO definition of the moderate case- Pneumonia with no signs of severe disease-Adolescent or adult with the presence of clinical features of dyspnea and or hypoxia, fever, cough, including SpO2

Exclusion criteria

Exclusion criteria: Those who are not willing to participate, patients with severe co- morbidities such as uncontrolled Diabetes, Liver disease, Renal disorders, uncontrolled Hypertension, pregnant and lactating women and severe COVID-19.

Design outcomes

Primary

MeasureTime frame
Primary outcome: Efficacy can be evaluated by a reduction in inflammatory markers and time (No. of days) of reduction of detectable SARS-CoV2 viral RNA in the RT PCR assays from randomization. Secondary outcome: Time from randomization and administration of medicine to recovery is expected to be lesser in the test group Timepoint: Day0 to Day 4

Secondary

MeasureTime frame
duration of stay in hospitalTimepoint: day 0- day 4

Countries

India

Contacts

Public ContactDrSailaja Vani B

ESIC Medical College and Hospital

drsailajavanibatchu@gmail.com9440477048

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026